316,614 Shares in Editas Medicine, Inc. $EDIT Bought by Nuveen LLC

Nuveen LLC bought a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) in the 1st quarter, Holdings Channel.com reports. The fund bought 316,614 shares of the company’s stock, valued at approximately $367,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of EDIT. Balyasny Asset Management L.P. boosted its position in shares of Editas Medicine by 647.3% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,300,604 shares of the company’s stock worth $1,652,000 after acquiring an additional 1,126,569 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Editas Medicine by 46.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,657,000 shares of the company’s stock worth $2,104,000 after acquiring an additional 528,000 shares in the last quarter. Tang Capital Management LLC acquired a new position in shares of Editas Medicine during the 4th quarter worth about $508,000. XTX Topco Ltd boosted its position in shares of Editas Medicine by 352.5% during the 1st quarter. XTX Topco Ltd now owns 475,381 shares of the company’s stock worth $551,000 after acquiring an additional 370,325 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Editas Medicine by 21.4% during the 4th quarter. Two Sigma Investments LP now owns 1,649,072 shares of the company’s stock worth $2,094,000 after acquiring an additional 290,483 shares in the last quarter. 71.90% of the stock is owned by institutional investors and hedge funds.

Editas Medicine Stock Performance

Editas Medicine stock opened at $2.76 on Friday. Editas Medicine, Inc. has a fifty-two week low of $0.91 and a fifty-two week high of $4.12. The company has a market capitalization of $248.18 million, a P/E ratio of -0.97 and a beta of 2.16. The stock has a 50-day simple moving average of $2.71 and a 200-day simple moving average of $2.00.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.22). The company had revenue of $3.58 million for the quarter, compared to analysts’ expectations of $1.81 million. Editas Medicine had a negative net margin of 608.88% and a negative return on equity of 200.25%. As a group, analysts forecast that Editas Medicine, Inc. will post -2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on EDIT shares. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Editas Medicine in a research report on Friday. Wall Street Zen cut Editas Medicine from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Robert W. Baird upped their price objective on Editas Medicine from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. Finally, Wells Fargo & Company upped their price objective on Editas Medicine from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Editas Medicine has a consensus rating of “Hold” and an average price target of $5.10.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.